Gregory Ciongoli
Fortuna: 14 M $ al 30/09/2026
Fortuna: 14 M $ al 30/09/2026
Mr. Gregory A. Ciongoli is an Independent Director at Gossamer Bio, Inc., an Independent Director at REGENXBIO, Inc., a Chairman at Atara Biotherapeutics, Inc. and a Managing Partner at Adiumentum Capital Management LLC.
He is on the Board of Directors at Gossamer Bio, Inc., REGENXBIO, Inc. and Zymeworks, Inc. Mr. Ciongoli was previously employed as a Partner by The Baupost Group LLC.
He received his undergraduate degree from Woodrow Wilson School of Public & International Affairs and an MBA from Harvard Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ZYMEWORKS INC. 0,7 % | 12/01/2026 | 493.500 ( 0,7 % ) | 13 M $ | 30/09/2026 |
REGENXBIO, INC. 0,18 % | 27/08/2026 | 118.035 ( 0,18 % ) | 888 804 $ | 30/09/2026 |
| 09/06/2026 | 12.000 ( 0,12 % ) | 102 000 $ | 30/09/2026 | |
GOSSAMER BIO, INC. -.--% | 23/09/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Presidente | 03/09/2025 |
| ZYMEWORKS INC. | Director/Miembro de la Junta | 11/08/2025 |
| REGENXBIO INC. | Director/Miembro de la Junta | 25/08/2026 |
| GOSSAMER BIO, INC. | Director/Miembro de la Junta | 16/09/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 7 |
|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Finance |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Woodrow Wilson School of Public & International Affairs
Woodrow Wilson School of Public & International Affairs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.